Jade Biosciences (JBIO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
The 2026 Annual Meeting of Stockholders will be held virtually via live webcast on June 9, 2026, at 2:30 p.m. Pacific Time, following a time change from the originally scheduled morning session.
The meeting is accessible only to registered stockholders who have a unique control number, with registration required by June 7, 2026.
All other meeting details, including the record date of April 17, 2026, and proxy instructions, remain unchanged.
Voting matters and shareholder proposals
Stockholders are encouraged to vote their shares in advance using the methods described in the proxy materials.
Proxies already submitted remain valid; revocation instructions are provided in the proxy statement.
Board of directors and corporate governance
The notice and proxy materials are issued by order of the Board of Directors, signed by the Chief Legal Officer and Corporate Secretary.
Latest events from Jade Biosciences
- $135M financing extends runway to 2028, advancing JADE201's RA trial and autoimmune pipeline.JBIO
Investor Update9 Jul 2026 - JADE101 targets IgAN with superior efficacy, infrequent dosing, and strong preclinical validation.JBIO
ERA 2025 Conference9 Jul 2026 - JADE101 and JADE201 advance in clinical development, targeting large autoimmune markets with strong funding.JBIO
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Jade 101, a next-gen anti-APRIL for IGAN, enters clinic with pivotal data expected next year.JBIO
Stifel Virtual Immunology and Inflammation Forum8 Jul 2026 - JADE101 achieved ~70% IgA reduction at 12 weeks with strong safety and Q12W dosing potential.JBIO
Study update26 Jun 2026 - Advancing potent antibody therapies for autoimmune diseases with strong financial backing.JBIO
2026 Bloom Burton & Co. Healthcare Investor Conference18 Jun 2026 - Lead autoimmune therapy JADE101 shows strong efficacy; $311M cash supports pipeline progress.JBIO
Company presentation1 Jun 2026 - Advancing high-affinity autoimmune therapies with strong cash position and key trials in 2026–2027.JBIO
Company presentation8 May 2026 - Registering 39.5M shares for resale, nearly 58% of stock, with major investor concentration.JBIO
Registration filing8 May 2026